Arctoris, an Oxford-based research company operating a fully automated drug discovery platform, has appointed three distinguished experts as members of its Advisory Board: Beth J Hoffman PhD, Prof. Khusru Asadullah MD, and Stanley Lapidus.
In an exclusive agreement with Bionomics Limited, Australia’s Carina Biotech will create Chimeric Antigen Receptor T cells (CAR-T cells) and other adoptive cell therapies to the leucine-rich repeat-containing G-protein coupled receptor 5 (LGR5) using the first-in-class humanised antibody BNC101 developed by Bionomics.
BioMedion, a global Compliance Management Software company providing controlled content and raw data management solutions for the life science industry, has acquired the Compliance Division of arivis, a provider of regulatory software and biomedical 3D and big image data software solutions.
Nordic Capital and Astorg have jointly acquired acquire Cytel Inc. from New Mountain Capital. Cytel is one of the largest providers of statistical software and advanced analytics for clinical trial design and biometrics execution.
Seattle, US-based LSBio, a leading provider of antibodies and life science research reagents, has acquired UK-based Absolute Antibody and its sister company Kerafast. Terms of the transaction were not disclosed.
The new Open Research Europe (ORE) platform – funded by the European Commission – is now up and running.
Due to promising results, Porvair Sciences has agreed with its collaborative partners to make additional investment in the CEAT project which aims to dramatically improve the diagnosis and treatment of ovarian cancer.
UK-based Mogrify has secured the assignment of the foundational intellectual property (IP) underpinning its core direct cell conversion technology (Mogrify V1) and extended the method to allow for the inclusion of new sources of data and more accurate transcription factor predictions (Mogrify V2). The expansion of rights allows the Company to bring the latest version […]
Novigenix SA Switzerland, a pioneer in immuno-transcriptomics for precision medicine, will lead a consortium, including PamGene International and Radboud University (The Netherlands), to develop a blood based multi-omics test to predict response to immune checkpoint inhibitors in cancer. The consortium has been awarded a grant up to €1 million under the Eurostars programme.
Dutch biotech company Pepscope, offering endogenous protein kinase activity profiling technologies, has secured €4.3 million funding to further develop and commercialize their lead product QuantaKinome.